Published Date: 13 Mar 2023
Hemophilia A is a rare bleeding disorder caused by a genetically encoded factor VIII mutation that affects blood clotting. sick...
Read Full NewsIn patients with newly diagnosed fibromyalgia who have prominent symptoms of anxiety and depression, remission of depression — not pain reduction alone — determines clinical improvement.
Most ADHD coaches do not have behavioral health training, a study finds, but experts say peer support can help people navigate living with the condition.
In the long term, stereotactic body radiotherapy carries a lower risk for biochemical failure vs high-dose rate brachytherapy for men with intermediate-risk prostate cancer.
1.
Do I have prostate cancer? Why a simple PSA blood test alone won't give you the answer
2.
Prostate cancer screening program beneficial in top decile of polygenic risk score
3.
Bladder cancer link to explosive ordnance exposure among Army veteran bomb disposal officers
4.
Getting More Done With Less Blood.
5.
Q&A: Odds of surviving cancer drop drastically when credit score dips
1.
Unlocking the Secrets of Squamous Cell Carcinoma: New Hope for Patients
2.
An Overview Of Daunorubicin: What Is It Used For And How Does It Work?
3.
Unlocking the Potential of Leukemia Treatment: A New Hope for Patients
4.
An Overview Of Serum Osmolality: What Is It And How Can It Help You?
5.
Frontiers in Cancer Therapeutics: U.S. Oncology Trials and Drug Discovery Trends
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
3.
Should We Use DARA Up Front As First-Line Therapy in MM?
4.
Virtual Case Study on Elephantiasis of Lower Limb- An Initiative by Hidoc Dr.
5.
"Lorlatinib Upfront": A Niche but Powerful Option For ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation